Australia's most trusted
source of pharma news
Monday, 16 March 2026
Posted 16 March 2026 AM
Twelve drugs that secured a recommendation at the PBAC’s November 2025 meeting have since stalled in the PBS listing process with the submissions for reimbursement marked inactive.
The list includes big names such as Biogen’s Skyclarys – the first treatment for the rare genetic disease Freiedreich ataxia and Apellis’ Syfovre, which was the only TGA approved treatment for geographic atrophy up until recently when Astellas Pharma’s Izervay was approved.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.